Compare FNWB & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWB | RVPH |
|---|---|---|
| Founded | 1923 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9M | 71.0M |
| IPO Year | 2015 | N/A |
| Metric | FNWB | RVPH |
|---|---|---|
| Price | $9.35 | $0.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $13.50 | $3.33 |
| AVG Volume (30 Days) | 35.2K | ★ 8.4M |
| Earning Date | 01-28-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $54,052,000.00 | N/A |
| Revenue This Year | $31.86 | N/A |
| Revenue Next Year | $10.64 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.47 | N/A |
| 52 Week Low | $6.05 | $0.25 |
| 52 Week High | $12.10 | $2.17 |
| Indicator | FNWB | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 30.18 |
| Support Level | $9.30 | $0.27 |
| Resistance Level | $10.08 | $0.34 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 3.82 | 9.29 |
First Northwest Bancorp is a bank holding company and a financial holding company and is engaged in banking activities through its wholly owned subsidiary, First Fed Bank, as well as certain non-banking financial activities. It includes deposit and lending transactions that are supplemented with other borrowing and investing activities. The bank's principal lending activities are focused on first lien one- to four-family mortgage loans, commercial and multi-family real estate loans, construction and land loans, commercial business loans, and consumer loans.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.